TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis

• Published in: Cancer Immunology, Immunotherapy Vol. 58; no. 3; pp. 361 - 371
• Main Authors: Djafarzadeh, Roghieh, Milani, Valeria, Rieth, Nicole, von Luettichau, Irene, Skrablin, Petra S, Hofstetter, Monika, Noessner, Elfriede, Nelson, Peter J
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Berlin/Heidelberg : Springer-Verlag 01.03.2009; Springer-Verlag; Springer; Springer Nature B.V
• Subjects: Angiogenesis; Antineoplastic agents; Apoptosis; Biological and medical sciences; Biology; Cancer Research; Cancer therapies; Cell death; Cell growth; Cell Proliferation; Cell Separation; Cell Survival; Cloning; Dermatology; fas Receptor - metabolism; Flow Cytometry; Glycosylphosphatidylinositols - metabolism; Humans; Hyperthermia; Hyperthermia, Induced; Immunology; Immunotherapy; Matrix Metalloproteinase 2 - metabolism; Matrix Metalloproteinase 9 - metabolism; Medical prognosis; Medical sciences; Medicine; Medicine & Public Health; Melanoma; Melanoma - therapy; Metastasis; Oncology; Original; Original Article; Pharmacology. Drug treatments; Proteins; Skin cancer; Skin Neoplasms - pathology; Skin Neoplasms - therapy; Tissue Inhibitor of Metalloproteinase-1 - metabolism; Treatment Outcome; Tumors; Tumors of the skin and soft tissue. Premalignant lesions; Germany; TIMP-1-GPI; Hyperthermic therapy; Melanoma; Apoptosis; Drug combination; Tissue inhibitor metalloproteinase 1; Malignant tumor; Sensitivity; Treatment; Cell death; Immunotherapy; Malignant melanoma; Fas Antigen; Cancer

Resistance to apoptosis is a prominent feature of malignant melanoma. Hyperthermic therapy can be an effective adjuvant treatment for some tumors including melanoma. We developed a fusion protein based on the tissue inhibitor of matrix metalloproteinase-1 linked to a glycosylphosphatidylinositol anc...